560 Shares in Cencora, Inc. $COR Purchased by Hilltop National Bank

Hilltop National Bank bought a new stake in Cencora, Inc. (NYSE:COR) during the 2nd quarter, Holdings Channel.com reports. The firm bought 560 shares of the company’s stock, valued at approximately $168,000.

A number of other large investors have also recently bought and sold shares of COR. Price T Rowe Associates Inc. MD lifted its position in shares of Cencora by 8.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Wellington Management Group LLP increased its stake in Cencora by 7.2% in the 1st quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock valued at $1,507,599,000 after buying an additional 363,402 shares during the last quarter. Boston Partners lifted its position in Cencora by 8.1% during the 1st quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after buying an additional 404,093 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after buying an additional 1,364,433 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Cencora by 9.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock valued at $475,890,000 after acquiring an additional 154,311 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 2.0%

Shares of Cencora stock opened at $302.54 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The business has a fifty day simple moving average of $294.68 and a two-hundred day simple moving average of $290.25. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $315.23. The company has a market capitalization of $58.66 billion, a price-to-earnings ratio of 31.13, a P/E/G ratio of 1.41 and a beta of 0.63.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.21. The company had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 earnings per share. Research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 22.63%.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Cencora in a report on Saturday, September 27th. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Wells Fargo & Company boosted their target price on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Finally, Jefferies Financial Group upped their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $311.25.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the sale, the chief executive officer directly owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. This trade represents a 11.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 55,993 shares of company stock worth $16,292,923. 10.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.